Vaccine adjuvants: Current state and future trends

@article{Petrovsky2004VaccineAC,
  title={Vaccine adjuvants: Current state and future trends},
  author={Nikolai Petrovsky and Julio C{\'e}sar Aguilar},
  journal={Immunology and Cell Biology},
  year={2004},
  volume={82}
}
The problem with pure recombinant or synthetic antigens used in modern day vaccines is that they are generally far less immunogenic than older style live or killed whole organism vaccines. This has created a major need for improved and more powerful adjuvants for use in these vaccines. With few exceptions, alum remains the sole adjuvant approved for human use in the majority of countries worldwide. Although alum is able to induce a good antibody (Th2) response, it has little capacity to… Expand
Improvements in Adjuvants for New-Generation Vaccines
TLDR
There remains a need for improved adjuvants that enhance strong T-cell immunity and protective antibody response and a logical approach to the development of new and more effective vaccine adjuvant requires a better understanding of the action of adjuvant-antigen formulations. Expand
Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.
TLDR
The development of new adjuvants which are able to promote broad and sustained immune responses at systemic and mucosal levels and which are currently under preclinical or clinical development will be described in this chapter. Expand
Commercial Opportunities Created by New Vaccine Adjuvant Technologies
Introduction O f all medical innovations, vaccines have had by far the greatest impact in reducing the morbidity and mortality of infectious diseases. Although antigens have always been the leadExpand
Immune modulators with defined molecular targets: Cornerstone to optimize rational vaccine design
TLDR
The development of new adjuvants which are able to promote broad and sustained immune responses at systemic and mucosal levels and are currently under preclinical or clinical development will be described in this chapter. Expand
Carbohydrate-based immune adjuvants
The role for adjuvants in human vaccines has been a matter of vigorous scientific debate, with the field hindered by the fact that for over 80 years, aluminum salts were the only adjuvants approvedExpand
Polysaccharides: Candidates of promising vaccine adjuvants.
TLDR
Polysaccharide-based compounds and formulations are potential vaccine adjuvant candidates because they can act as pathogen-associated molecular patterns and recognize pattern recognition receptors on immune cells, followed by triggering innate immunity and regulating adaptive immunity. Expand
New Generation Vaccines : Need for Safe and Improved Adjuvants
TLDR
To address life-threatening pandemic diseases and ever evolving drugresistant microbial infections worldwide, designing vaccines with safe and efficacious adjuvant is a major challenge for the scientific community that needs to be addressed systematically. Expand
Trends in Adjuvant and Vaccine Delivery Systems
TLDR
The gradual advances made in antigen discovery need to be complemented with new generation adjuvants for multidimensional effects and the foresight of the eminent threat warrants drastic revolution in this sector. Expand
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
TLDR
The biggest remaining challenge in the adjuvant field is to decipher the potential relationship between adjuvants and rare vaccine adverse reactions, such as narcolepsy, macrophagic myofasciitis or Alzheimer’s disease. Expand
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
TLDR
The overall concept of adjuvants in vaccine technology is reviewed with special focus towards the prospects of controlled release antigens, with particular focus towards biodegradable polymer microparticles. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 149 REFERENCES
Adjuvants for human vaccines--current status, problems and future prospects.
TLDR
Progress has been made on development, isolation and chemical synthesis of alternative adjuvants such as derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS21, MF-59 and immunostimulating complexes (ISCOMS). Expand
Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responses
TLDR
Inulin‐derived adjuvants that principally stimulate the innate immune system through their ability to activate the alternative complement pathway have proven ability to induce both cellular and humoral immunity, and offer great potential for use in a broad range of prophylactic and therapeutic vaccines. Expand
Adjuvants and delivery systems for viral vaccines--mechanisms and potential.
TLDR
The role of adjuvants in modern viral vaccine technology and their influence on the immune system are the subject of this review. Expand
Future prospects for vaccine adjuvants.
TLDR
The currently known agents capable of immunopotentiation and possible strategies for their use in future vaccines are discussed. Expand
Adjuvants in perspective.
  • F. Vogel
  • Medicine
  • Developments in biological standardization
  • 1998
TLDR
Novel adjuvant formulations can be designed that favour the development of Th1 (type 1) or Th2 (type 2) immune responses to vaccine antigens, including vaccines against HIV-1. Expand
Synthetic immunomodulators and synthetic vaccines.
  • C. Leclerc, F. Vogel
  • Biology, Medicine
  • Critical reviews in therapeutic drug carrier systems
  • 1986
TLDR
One MDP derivative presently under clinical trials has been shown to be adjuvant active but is devoid of pyrogenicity, and the mechanisms of activity of these MDP and derivative molecules will be discussed. Expand
The iscom structure as an immune-enhancing moiety: experience with viral systems.
The “ideal” vaccine should meet the following requirements: the induction of a long-lasting antibody response of biologically active antibodies, which should be elicited even in the presence ofExpand
Immunological Adjuvants and Vaccines
TLDR
This book contains the proceedings of the 1st NATO Advanced Studies Institute "Immunological Adjuvants and Vaccines" held in Cape Sounion Beach, Greece during 24 June-5 July, 1988. Expand
Special Section:Future Trendsin Vaccination: Advances in cancer vaccine development
TLDR
The optimal vaccine will elicit both humoral and cellular immunity in the patients as both parameters have been positively correlated with the induction of beneficial clinical responses and the choice of adjuvant, costimulation and delivery mode greatly determines the outcome of vaccinations. Expand
Adjuvant influenza vaccines.
TLDR
A trial in Britain has shown equally good adjuvant properties of the reversed emulsion incorporating influenza virus vaccine so far as serological response is concerned, although it has not yet been conducted on a scale that would allow of adequate evaluation of the likelihood of delayed local reactions. Expand
...
1
2
3
4
5
...